H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on DTIL stock, giving a Buy rating on March 20.
Patrick Trucchio has given his Buy rating due to a combination of factors that highlight Precision BioSciences’ promising advancements in its in vivo gene editing pipeline. The company’s strategic focus on ARCUS-based therapeutics is gaining traction, with key clinical milestones expected in the near term. This momentum is supported by successful clinical outcomes, such as the PBGENE-HBV program, which has shown the first clinical proof-of-concept for in vivo gene editing in chronic hepatitis B. Additionally, the iECURE-OTC program’s complete clinical response in the first patient further underscores the potential of Precision’s ARCUS platform.
Moreover, Precision’s preclinical muscle-targeted DNA excision program, PBGENE-DMD, presents a novel approach to treating Duchenne muscular dystrophy, reinforcing the company’s innovative edge. With a robust financial position and multiple revenue-generating partnerships, Precision BioSciences is well-positioned for significant growth. These factors collectively justify the Buy rating and the optimistic price target set by Trucchio.
In another report released on March 20, JonesTrading also maintained a Buy rating on the stock with a $30.00 price target.